Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, Klein S, Kim Y, MacLeod AR, Sugimoto K, Yoshikawa K, Nishio K, Uemura H.
De Velasco MA, et al. Among authors: davies br.
JCI Insight. 2019 Sep 5;4(17):e122688. doi: 10.1172/jci.insight.122688.
JCI Insight. 2019.
PMID: 31484823
Free PMC article.